文献速递妇产影像

孕激素预处理卵巢刺激与GnRH方案在辅助生殖中的比较:系统综述与荟萃分析

Progestogen-primed ovarian stimulation vs GnRH antagonists and/or agonists for women undergoing assisted reproduction: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2026-07-09

该研究纳入20项随机对照试验共4430例接受辅助生殖的妇女,比较PPOS与GnRH拮抗剂和/或激动剂方案。结果显示,与GnRH拮抗剂相比,PPOS的活产率显著更高(RR 1.13,95%CI 1.02-1.25,中等确定性),且获卵数更多。无中重度OHSS事件发生,提示PPOS是可行的替代方案。

要点

  • PPOS相比GnRH拮抗剂方案活产率更高(RR 1.13)且获卵数更多。
  • 两组均未观察到中重度OHSS事件,提示卵巢过度刺激风险低。
  • PPOS适合不计划新鲜胚胎移植的卵巢刺激患者。

核心结论

  • 中等至低确定性证据表明,PPOS相比GnRH拮抗剂方案获卵数更多且首个胚胎移植周期活产率更高。
  • PPOS在所有分析队列中未观察到重度OHSS病例,安全性表现良好。
  • 对于不打算进行新鲜胚胎移植的妇女,PPOS是GnRH类似物的可行且潜在更优的替代方案。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus、Web of Science及主要临床试验注册库,检索时间截至2025年11月11日。
  • 纳入20项随机对照试验,共4430例接受体外受精或卵胞浆内单精子注射的妇女,使用自身卵母细胞、供卵或生育力保存。
  • PPOS方案药物包括醋酸甲羟孕酮、地屈孕酮、微粒化黄体酮;对照方案为GnRH拮抗剂(17项)、GnRH激动剂(2项)及激动剂联合拮抗剂(1项)。
  • 偏倚风险评估采用Cochrane RoB 2工具,可信度评价采用INSPECT-SR工具,证据确定性采用GRADE方法。
  • 主要结局为每随机分组妇女的活产率;次要结局包括临床妊娠率、早发LH峰、中重度OHSS、取卵取消率及获卵数。

诊断标准与关键数值

  • PPOS对比GnRH拮抗剂:活产率RR 1.13(95%CI 1.02-1.25),P=0.02,中等确定性;获卵数MD 0.88(95%CI 0.27-1.50),P=0.005,低确定性。
  • PPOS对比GnRH拮抗剂:排除高偏倚风险研究后活产率RR 1.11(95%CI 1.00-1.23),P=0.05,结果稳健。
  • PPOS对比GnRH拮抗剂:取卵取消率RR 0.82(95%CI 0.42-1.57),P=0.55;早发LH峰RR 0.49(95%CI 0.05-4.94),P=0.54,均无显著差异。
  • PPOS对比GnRH激动剂:活产率RR 0.97(95%CI 0.74-1.26),P=0.80;中重度OHSS RR 0.14(95%CI 0.01-2.74),P=0.20;获卵数MD 0.91(95%CI -0.55至2.37),P=0.22,均无显著差异。
  • PPOS对比GnRH激动剂联合拮抗剂方案:活产率RR 1.01(95%CI 0.80-1.27),P=0.93;取卵取消率RR 0.79(95%CI 0.38-1.67),P=0.54,均无显著差异。

临床应用与阅片要点

  • PPOS可作为不计划新鲜胚胎移植患者的一线卵巢刺激替代方案。
  • 采用PPOS方案时需注意其口服给药便利性和较低药物成本的临床优势。
  • 该方案在GnRH拮抗剂对照中显示出更高的获卵数与活产率,但不能用于计划新鲜移植者。
  • 获悉PPOS对比GnRH拮抗剂在早发LH峰与取卵取消率方面无显著差异,临床选择时可纳入安全性考量。

局限性

  • 无研究达到整体低偏倚风险:13项有部分疑虑,7项为高偏倚风险;5项研究在INSPECT-SR评估中发现严重可信度问题。
  • 多数比较的证据确定性为低至非常低,尤其是PPOS对比GnRH激动剂及联合方案仅有2项和1项研究。
  • 部分结局事件数较少或为零,如早发LH峰和取卵取消率,影响RR估计的精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare the effectiveness and safety of progestogen-primed ovarian stimulation (PPOS) vs gonadotropin-releasing hormone (GnRH) antagonists and/or agonists for women undergoing assisted reproduction.

METHODS: PubMed, Scopus, Web of Science and major clinical trial registries were searched from inception until 11 November 2025 for randomized controlled trials (RCTs) comparing PPOS (e.g. medroxyprogesterone acetate, dydrogesterone, micronized progesterone) with GnRH antagonists and/or GnRH agonists in women undergoing ovarian stimulation for in-vitro fertilization or intracytoplasmic sperm injection using their own oocytes, for oocyte donation or for fertility preservation. The primary outcome was the live-birth rate per woman randomized. Secondary outcomes included rates of clinical pregnancy, premature luteinizing hormone (LH) surge, moderate/severe ovarian hyperstimulation syndrome (OHSS) and oocyte pick-up (OPU) cancelation, and the number of oocytes retrieved. Risk of bias was assessed using the Cochrane revised Risk of Bias (RoB 2) tool and trustworthiness was evaluated using the INveStigating ProblEmatic Clinical Trials in Systematic Reviews (INSPECT-SR) tool. We performed random-effects meta-analyses to calculate relative risk (RR) and mean difference (MD) with 95% CI, as appropriate. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

RESULTS: Twenty RCTs involving 4430 participants were included. No study was at low overall risk of bias; 13 had some concerns and seven were at high risk. INSPECT-SR identified serious trustworthiness concerns in five studies. PPOS was compared with GnRH antagonists in 17 studies, GnRH agonists in two studies and a combined GnRH agonist + antagonist regimen in one study. Compared with GnRH antagonists, PPOS was associated with a significantly higher live-birth rate (RR, 1.13 (95% CI, 1.02-1.25); P = 0.02; moderate certainty). This finding remained robust on sensitivity analysis excluding the study with a high risk of bias (RR, 1.11 (95% CI, 1.00-1.23); P = 0.05). PPOS was also associated with a higher number of oocytes retrieved compared with GnRH antagonists (MD, 0.88 (95% CI, 0.27-1.50); P = 0.005; low certainty). There were no significant differences in the rates of OPU cancelation (RR, 0.82 (95% CI, 0.42-1.57); P = 0.55; low certainty) or premature LH surge (RR, 0.49 (95% CI, 0.05-4.94); P = 0.54) between groups. No moderate/severe OHSS events were reported in either group across 10 studies. For the comparison of PPOS vs GnRH agonists, there were no significant differences in live-birth rate (RR, 0.97 (95% CI, 0.74-1.26); P = 0.80; low certainty), moderate/severe OHSS (RR, 0.14 (95% CI, 0.01-2.74); P = 0.20; very low certainty) or number of oocytes retrieved (MD, 0.91 (95% CI, -0.55 to 2.37); P = 0.22; low certainty), with zero events reported for premature LH surge and OPU cancelation in both groups. In the comparison of PPOS vs combined GnRH agonist + antagonist regimen, there were no significant differences in live-birth rate (RR, 1.01 (95% CI, 0.80-1.27); P = 0.93; very low certainty) or OPU cancelation (RR, 0.79 (95% CI, 0.38-1.67); P = 0.54; very low certainty), with no premature LH surges reported.

CONCLUSIONS: Current evidence of moderate-to-low certainty suggests that PPOS results in a higher number of oocytes and a higher live-birth rate in the first embryo-transfer cycle compared with a GnRH antagonist protocol. PPOS appears safe, with no case of severe OHSS observed across the analyzed cohorts. Given its oral administration, lower drug cost and demonstrated efficacy, PPOS represents a viable and potentially superior alternative to GnRH analogs for women undergoing ovarian stimulation for whom fresh-embryo transfer is not intended. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Martins, Nastri. Progestogen-primed ovarian stimulation vs GnRH antagonists and/or agonists for women undergoing assisted reproduction: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2026. PMID: 42425545. doi:10.1002/uog.70267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。